Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
← catalyst calendarNCT04957485 · readout in 134 d
Sponsored by SIGA Technologies (industry) · SIGA — their whole pipeline →. With United States Department of Defense.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
100actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-05 | actual | When the study began enrolling |
| Primary completion | 2027-01-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Smallpox
Interventions
- Drug: Tecovirimat — also filed as TPOXX
- Drug: Smallpox and Mpox Vaccine — also filed as JYNNEOS
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFAdverse Events
measured 59 Days
Immunogenicity
measured Day 43
Permalink · SIGA's whole pipeline · Catalyst calendar · Every registered study · What changed